PII: S0031-9422(98)00040-5

5α , 7α (H)-6,8-CYCLOEUDESMA- 1β , 4β -DIOL FROM THE FLOWER BUDS OF *MAGNOLIA FARGESII*

KEUN YOUNG JUNG, DONG SEON KIM, SI-HYUNG PARK, IM SEON LEE, SEI RYANG OH, JUNG JOON LEE, EUN-HEE KIMT, CHAEJOON CHEONGT and HYEONG-KYU LEE*

Natural Product Biosynthesis Research Unit, Korea Research Institute of Bioscience and Biotechnology, Yusong P.O. Box 115, Taejon 305-600; † Magnetic Resonance Group. Korea Basic Science Institute, Taejon 305-333, Korea

(Received in revised form 22 October 1997)

Key Word Index—*Magnolia fargesii*; Magnoliaceae; cycloeudesmane-type sesquiterpene: 5α , 7α (H)-6,8-cycloeudesma-1 β . 4β -diol.

Abstract—From the Chinese crude drug *shin-i*, the flower buds of *Magnolia fargesii*, a new cycloeudesmane-type sesquiterpene, 5α , 7α (H)-6,8-cycloeudesma-1 β , 4β -diol, was isolated. The structure was elucidated by means of various NMR techniques. This compound has biogenetic significance because it is a plausible intermediate of the oppositol-type compound such as homalomenol A reported from this plant. © 1998 Elsevier Science Ltd. All rights reserved

INTRODUCTION

The dried flower buds of *Magnolia fargesii* has a history of use for the treatment of nasal congestion with headache, sinusitis, and allergic rhinitis [1]. Pharmacological studies have revealed that *shin-i* has uterus-stimulating, hypotensive, antifungal, and skeletal muscle contracting effects [2, 3]. In previous reports on chemical investigations of this plant, many kinds of essential oils, lignans, neolignans and sesquiterpenes have been found and pharmacological activities of these lignans from *shin-i*, Ca²⁺ antagonistic activity and platelet activating factor (PAF) antagonistic activity were revealed [4–10].

Recently, we reported the structural elucidation of the four sesquiterpenes, oplopanone, oplodiol, homalomenol A and 1β , 4β , 7α -trihydroxyeudesmane isolated from the ethyl acetate extracts of this plant besides seven know phenolic lignans with PAF antagonistic activity [11]. In a continuing study, we have isolated a new cycloeudesmane-type sesquiterpene, 5α , 7α (H)-6,8-cycloeudesma-1 β , 4β -diol (1) from this plant.

RESULTS AND DISCUSSION

An ethyl acetate extract of the flower buds of M. fargesii was fractionated by repeated column chro-

1

matography (silica gel and RP-18) to yield compound as colorless needles.

Compound 1 revealed an absorption at 3401 cm⁻¹ in its IR spectrum suggesting the presence of a hydroxyl group. The EI mass spectrum of 1 exhibited a molecular ion peak at m/z 238 and the significant fragmentation ion peaks at m/z 220 [M-H₂O]⁺, 202 [M-2H₂O]⁻, 195 [M-C₃H₇]⁻, 177 [220-C₃H₇]⁺ and/or [195-H₂O]⁺, indicating the presence of at least two hydroxyl groups and a propyl group.

The ¹H NMR spectrum of 1 in CDCl₃ showed a methine proton attached a hydroxyl function at δ 3.33 (1H. dd, J = 10.9 and 4.4 Hz), two tertiary methyl proton at δ 1.30 (3H, s) and 1.17 (angular Me, s), and an isopropyl group at δ 0.93 (3H. d, J = 6.6 Hz), 0.97 (3H, d, J = 6.6 Hz) and 0.98 (1H. m), which was further confirmed by ¹H–¹H COSY and HMBC spectra. The ¹²C NMR and DEPT spectra suggested that the skeleton consisted of 15 carbons: four methyls, three methylenes, six methines and two quartenary carbons. From the HMQC spectrum of 1, the chemi-

^{*}Author to whom correspondence should be addressed. Tel. +82-42-860-4413; Fax. +82-42-860-4608; e-mail: hykylee@kribb4680.kribb.re.kr.

Table 1. ¹H and ¹³C NMR Assignments for 5α , 7α (H)-6,8-cycloeudesma-1 β , 4β -diol (1)

Position	'Н		¹³ C	
	$\delta_{H}{}^{a}$	$\delta_{ extsf{H}}^{ extsf{ b}}$	$\delta_{ m C}{}^{\scriptscriptstyle 4}$	$\delta_{c}^{\mathfrak{b}}$
1	3.33 (1H, dd, 10.9, 4.4)	3.27 (1H, dd, 11.4, 4.3)	78.04 (<i>d</i>)	78.99
2	1.72 (1H, m)	1.76 (1H, m)	28.20(t)	28.89
	1.61 (1H, m)	1.49 (1H, m)		
3	1.66 (1H, m)	1.64 (1H, m)	39.57 (t)	40.42
	1.35 (1H, m)	1.38 (1H. m)		
4			70.98(s)	71.52
5	0.71 (1H, d, 4.6)	0.69 (1H, d, 5.7)	60.61 (d)	62.15
6	1.17 (1H, m)	1.32 (1H. m)	23.97(d)	25.37
7	0.52(1H,m)	0.45 (1H, ddd, 8.8, 3.0, 3.0)	49.89 (d)	51.12
8	1.18 (1H, m)	1.13 (1H. m)	24.37 (d)	25.50
9	0.91 (1H, m)	0.83 (1H, m)	44.48 (t)	45.81
	1.84 (1H, m)	1.82 (1H, m)		
0			58.03 (s)	59.40
1	0.98 (1H, m)	0.88 (1H, m)	32.48(d)	33.94
2	0.93 (3H, d, 6.6)	0.96 (3H, d, 6.5)	21.87(q)	22.29
3	0.97 (3H, d, 6.6)	0.98 (3H, d, 6.5)	21.73(q)	22.29
14	1.17 (3H, s)	1.16 (3H, d, 0.9)	15.51 (q)	16.23
15	1.30 (3H, s)	1.28 (3H, s)	30.28(q)	30.54

[&]quot;Assignments were based on DEPT, 1H-1H COSY, HMQC and HMBC in CDCl₃,

cal shifts of protonated carbons were assigned as listed in Table 1. Characteristic 13 C NMR signals of δ 78.04 (CH), 70.98 (C), 58.03 (C), 30.28 (CH₃) and 15.51 (CH₃) suggested a eudesmane skeleton with one secondary and one tertiary hydroxyl group. In addition, three methine carbon signals at δ 23.97, 24.37 and 49.89, which appeared in the significantly high field region, indicated the presence of a 1.2,3-trisubstituted cyclopropane ring [12]. In the HMBC correlations, two methyl proton signals of an isopropyl group were correlated to the carbon signals at 32.48 (C-11) and 49.89 (C-7), and the latter was correlated with the proton signals at δ 0.71 (H-5) and 1.84 (H-9). Also, in the cyclopropane ring moiety, the methine carbon signals at δ 23.97 (C-6) and 24.37 (C-8) were correlated with the proton signal of H-5 and H-9, respectively. The methyl proton signal at δ 1.17 (H-14) was longrange-correlated to the methine carbon signal at δ 60.61 (C-5) to which the proton signals at δ 3.33 (H-1) and 0.52 (H-7) were correlated. All the remaining proton signals were correlated to proximate carbon signals through two and/or three bond connections as shown Fig. 1. Thus, the structure of 1 could be assigned from the above evidence; its stereochemistry was determined as described below.

The configuration of the hydroxyl group at C-1 was confirmed to be in the equatorial position (β) from the fact that the coupling constants (dd, J=10.9 and 4.4 Hz) of H-1 in the ¹H NMR spectrum indicated its axial position [13]. Regarding the configuration of the hydroxyl at C-4, an axial orientation (β) will result in deshielding of the methyl carbon (C-15) and a downfield shift in its resonance to approximately δ 30 [14.

15]. An equatorial orientation (α) results in the C-15 carbon having a chemical shift of approximately δ 25 [16, 17]. The corresponding signal observed in the ¹³C NMR spectrum is δ 30.28 and this value agrees well with the assignment of the axial orientation. The stereochemistry of C-7 was deduced through the observation of the NOESY spectrum of 1 in CD₃OD solution because the signals of H-6, H-8 and the methyl proton of C-14 in the ¹H NMR spectrum in CDCl₃ were very much overlapped. The NOESY spectrum of 1 showed strong interactions between the proton at δ 0.69 (H-5) and the proton at δ 0.45 (H-7), and no interaction of the proton at δ 1.16 (H-14) with H-7 and H-11. This result indicated that the configurations of the isopropyl moiety and the proton of C-7 are equatorial and axial orientations, respectively, as shown in the proposed structure (chair con-




Fig. 1. HMBC correlations for 5α , 7α (H)-6,8-cycloeudesma-1 β , 4β -diol (1). The arrow indicate correlations from proton to carbon.

^bMeasured in CD₃OD.

Scheme 1. The possible biogenetic conversion of 1 into homalomenol A (2).

formation). All of these findings established that the structure of 1 was 5α , 7α (H)-6,8-cycloeudesma-1 β , 4β -diol (1), a new cycloeudesmane-type sesquiterpene.

The reports of cycloeudesmane-type sesquiterpenes show that they are very rare in nature [18]. In the case of the 6,8-cycloeudesmane-type, Itokawa *et al.* [12] have reported the isolation of 1β -hydroxy-6,8-cyclo-4(15)eudesmene from the plant *Torilis japonica*. This compound was also obtained by the biomimetic reaction of epoxygermacrene-D with basic alumina [19]. Therefore, compound 1 has a biogenetic significance because it is a plausible intermediate of the oppositol-type of compound such as homalomenol A (2) [11] isolated from this plant (Scheme 1).

EXPERIMENTAL

Mps: Electrothermal 9100, uncorr. Optical rotation was recorded on Jasco DIP-370 digital polarimeter. The IR and UV spectra were recorded using a Magna 550 spectrophotometer in KBr pellet and a Milton Roy Spectronic 3000 Array spectrophotometer in MeOH soln, respectively. The EI-MS spectra were performed on a Hewlett-Packard 5889A. The ¹H NMR (300 MHz) and ¹³C NMR (75 MHz) spectra were recorded on a Bruker DRX-300 spectrometer and the chemical shifts were referenced to TMS as the internal standard. HMBC and NOESY data were recorded on a Bruker DMX-600 spectrometer. CC was carried out on Kieselgel 60 (Merck No. 9385 and 7729) and LiChroprep RP-18.

Plant material

The dried flower buds of *Magnolia fargesii* Cheng was purchased from Il-Shin Pharm. Co. (Taejon, Korea) which imported the material from China. A voucher specimen is deposited in our laboratory (NDC-052).

Extraction and isolation

The dried and pulverized flower buds of M. fargesii (3 kg) were extracted with MeOH at room temp. for several days. The MeOH extracts were concentrated under red. press. to give a residue (225 g). The residue was partitioned between n-hexane (40 g), EtOAc (109 g). n-BuOH (20 g) and H_2O , in the usual order. The

EtOAc extract was loaded on silica gel CC eluted with a stepwise solvent gradient of MeOH in CHCl₃ to afford nineteen subfractions. The subfr. 8 (3 g) was further purified by repeated RP-18 (MeOH-H₂O, 3:2) and SiO₂ CC (CHCl₃-MeOH, 99:1) to give compound 1 (24 mg).

5α,7α(H)-6,8-cycloeudesma-1β,4β-diol (I). Colorless needles in MeOH; mp 146–147°. [α] $_{\rm D}^{25}$ -4.0° (c 0.25, CHCl₃). IR [v] $_{\rm max}^{\rm KBr}$ cm $^{-1}$: 3401, 2949, 1015. EI-MS m/z (rel. int.): 238 [M] $^+$ (6), 220 (51), 205 (21), 202 (18), 195 (14), 187 (40), 177 (54), 159 (100). 1 H NMR (300 MHz): Table 1. 13 C NMR (75 MHz): Table

REFERENCES

- Namba, T., Coloured Illustrations of Wakan-Yaku (The Crude Drugs in Japan, China and Neighbouring Countries), Vol. II. Hoikusha Publishing, Osaka, 1980, pp. 127–129.
- Tang, W. and Eisenbrand, G., Chinese Drugs of Plant Origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine. Springer-Verlag, Berlin, 1992, pp. 639-646.
- Chen, C. C., Huang, Y. L., Chen, H. T., Chen, Y. P. and Hsu, H. Y., *Planta Medica*, 1988, 54, 438.
- 4. Miyazawa, M., Kasahara, H. and Kameoka, H., *Phytochemistry*, 1992, **31**, 3666.
- Miyazawa, M., Ishikawa, Y., Kasahara, H., Yamanaka, J. I. and Kameoka, H., *Phyto-chemistry*, 1994, 35, 611.
- 6. Miyazawa, M., Kasahara, H. and Kameoka, H., *Phytochemistry*, 1996, **42**, 531.
- 7. Chen, C. C., Huang. Y. L., Chen. H. T., Chen, Y. P., Hsu, H. Y. and Kuo, Y. H., Chemical and Pharmaceutical Bulletin, 1988, 36, 1791.
- Kakisawa, H., Kusumi, T., Hso, H. Y. and Chen, Y. P., Bulletin of Chemical Society of Japan, 1970, 43, 3631.
- Hwang, Y. L., Chen, C. C., Chen, Y. P., Hsu, H. Y. and Kuo, Y. H., Planta Medica, 1990, 56, 237.
- Pan, J. X., Hensens, O. D., Zink, D. L., Chang, M. N. and Hwang, S. B., *Phytochemistry*, 1987, 26, 1377.
- Jung, K. Y., Kim, D. S., Oh, S. R., Lee, I. S., Lee, J. J., Lee, H. K., Shin, D. H., Kim, E. H. and

- Cheong, C.-J., Archives Pharmacal Research, 1997, 20, 363.
- 12. Itokawa, H., Matsumoto, H. and Mihashi, S., *Chemistry Letters*, 1983, 1253.
- Nyasse, B., Tih, R. G., Sondengam, B. L., Martin, M. T. and Bodo, B., *Phytochemistry*, 1988, 27, 179
- 14. Herz, W. and Watanabe, K., *Phytochemistry*, 1983, **22**, 1457.
- 15. Sung, T. V., Steffan, B., Steglich, W., Klebe, G. and Adam, G., *Phytochemistry*, 1992, **31**, 3515.

- 16. Toyota, M. and Asakawa, Y., *Phytochemistry*, 1990, **29**, 3664.
- Zhao, Y., Yue, J.-M., He, Y.-N., Lin, Z.-W. and Sun, H.-D., *Journal of Natural Products*, 1997, 60, 545.
- Connolly, J. D. and Hill, R. A., Directory of Terpenoids, Vol. 1. Mono- and Sesquiterpenoids, Chapman & Hall, London, 1991, pp. 394– 397
- 19. Yamamura, S., Niwa, M., Ito, M. and Saito, Y., Chemistry Letters, 1982, 1681.